Isomorphic Labs raises $5 billion to push its AI-designed drugs towards clinical trials
Greenoaks and Sequoia Capital co-led the Series C, with a16z and Alphabet also investing. Demis Hassabis says the money will fund biology models, disease research and the first programmes heading to the clinic.